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ABSTRACT

AB-type protein toxins such as cholera toxin (CT) consist of a catalytic A subunit
and a cell-binding B subunit. CT proceeds through the secretory pathway in reverse,
termed retrograde trafficking, and is delivered to the endoplasmic reticulum (ER). In
order for the catalytic A1 subunit to become active it must separate from the rest of the
holotoxin, and this dissociation event occurs in the ER lumen. CTA1 assumes an
unfolded conformation upon dissociation from the holotoxin and is recognized by ERassociated degradation (ERAD), a quality control system that recognizes and exports
misfolded proteins to the cytosol for degradation by the 26S proteasome. CTA1 is not
degraded by the 26S proteasome because it has few sites for poly-ubitiquination, which
is recognized by the cap of the 26S proteasome for degradation. Thus, CTA1 escapes
the degradation of ERAD while at the same time using it as a transport mechanism into
the cytosol.
It was originally proposed that CTA1 is thermally stable and that ER chaperones
actively unfolded CTA1 for translocation to the cytosol. In contrast, we hypothesized
that the dissociated CTA1 subunit would unfold spontaneously at 37°C. This study
focused on the three conditions linked to CTA1 instability and translocation: (i) CTA1
dissociation from the holotoxin, (ii) the translocation-competent conformation of CTA1,
and (iii) the extraction of CTA1 from the ER into the cytosol. Disruption of any of these
events will confer resistance to the toxin. The original model suggested that PDI
actively unfolds CTA1 to allow for translocation. However, Fourier transform infrared
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spectroscopy (FTIR) and surface plasmon resonance (SPR) data we have gathered
demonstrated that PDI dislodges CTA1 from the rest of the holotoxin without unfolding
CTA1. Once released by the holotoxin, CTA1 spontaneously unfolds. PDI is thus
required for the toxicity of CT, but not as an unfoldase as originally proposed. CTA1
must maintain an unfolded conformation to keep its translocation-competent state.
Based on our model, if CTA1 is stabilized then it will not be able to activate the ERAD
translocation system. Our SPR and toxicity results demonstrated that treatment with 4phenylbutyrate (PBA), a chemical chaperone, stabilizes the structure of CTA1. This
stabilization resulted in a decrease in translocation from the ER to the cytosol and a
block of intoxication, which makes it a viable candidate for a therapeutic. Because
CTA1 exits the ER in an unfolded state, there must be a driving force for this
translocation. We hypothesized that Hsp90, a cytosolic chaperone, is responsible for
the translocation of CTA1 across the membrane. Previous research had shown Hsp90
to be present on the cytosolic face of the ER and had also shown that Hsp90 will refold
exogenously added proteins that enter the cytosol. Using drug treatments and RNAi,
we found that Hsp90 is required for the translocation of CTA1 from the ER lumen to the
cytosol, a brand new function for this chaperone.
We have provided evidence to support a new, substantially different model of
CTA1 translocation. CTA1 does not masquerade as a misfolded protein in order to
utilize ERAD for entry into the cytosol; it actually becomes misfolded and is treated as
any other ERAD substrate. The spontaneous unfolding of CTA1 is the key to its
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recognition by ERAD and ultimately its translocation into the cytosol. Host factors play
very important roles in intoxication by AB toxins and are targets for blocking intoxication.
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CHAPTER 1 INTRODUCTION
1.1 Intracellular Trafficking
Cells must use several endocytic paths in order to carry out many different
functions. The most well known of these mechanisms involves clathrin-coated
pits and vesicles (1, 2). Clathrin-dependent endocytosis is used to acquire
nutrients from the extracellular environment. This type of endocytosis occurs on
special coated pits localized on the plasma membrane. Ligands from the
extracellular environment bind via specific cell-surface receptors that trigger a
signaling cascade to recruit clathrin to the cytosolic face of the plasma
membrane. When clathrin is recruited to the plasma membrane it binds to other
clathrin molecules creating a mesh underlying the ligand receptor complex and
causing the plasma membrane to invaginate and pinch off. In addition to
clathrin-dependent endocytosis, internalization can proceed via either caveolaedependent endocytosis or much less studied mechanisms that do not utilize
either clathrin or caveolae. Caveolae-dependent endocytosis is characterized by
the involvment of the 22-kD membrane-associated protein, caveolin. Caveolae
are invaginated plasma membrane domains enriched in cholesterol and
glycosphingolipids (3-7). Caveolin binds cholesterol and aids in forming and
stabilizing the invaginated membrane domains; the loss of caveolin coat allows
for vesicle formation. Cells utilize the endomembrane system not only for
acquiring nutrients from the extracellular environment but also for the packaging
and shipping of proteins to their destination, namely secretion.
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The secretory pathway is the export pathway for the cell. Proteins that are
synthesized in the endoplasmic reticulum (ER) are packaged for transport to the
extracellular surface in an anterograde fashion. A secondary transport pathway
to maintain membrane homeostasis must offset the secretory pathway. This
retrograde pathway is used to recycle proteins and lipids involved in the
secretory pathway and takes places in three different steps: 1) transport from
endosomes, early (EE) or late (LE), to the trans-Golgi network (TGN); 2) intraGolgi transport; and 3) transport from the Golgi to the ER.
Transport from the endosomes-to-TGN has been shown to occur by two
routes. The first endosome-to-TGN traffic route is the Rab9-dependent pathway
(8, 9). This route is characterized by the involvement of the small GTPase Rab9.
Rab9 organizes the endosome membrane for transport to the TGN. The second
endosome-to-TGN transport pathway is thought to function between the recycling
endosomes, a subclass of the EE, via another small GTPase, Rab11, that
regulates membrane distribution inside the recycling endosomes (10).
The intra-Golgi transport pathway is yet unresolved. Anterograde
transport within the Golgi complex still needs to be elicudicated. It is possible
that transport occurs via vesicular carriers (11). Another argument is that
transport occurs via the maturation of Golgi cisternae (12). Both sides of the
argument are in agreement, however, that vesicle-mediated retrograde transport
within Golgi must occur to maintain Golgi homeostasis. Identification of the
machinery involved with intra-Golgi retrograde transport is difficult to confirm due
to the difficulty in interpretation of trafficking data.
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Retrograde traffic from the Golgi to the ER also utilizes multiple pathways.
Some proteins contain a KDEL sequence that acts as a retrieval sequence in the
Golgi (COPI-dependent) (13-15). Binding of KDEL-tagged proteins to the KDEL
receptor allows for the binding of the small GTPase Arf1. Activated Arf1 is
recruited to the cargo receptor complex. Arf1 then recruits COPI coat protein
complex which promotes vesicle formation. COPI coated vesicles are targeted to
the ER. In this manner the KDEL sequence acts as a retention tag for the ER. A
number of protein toxins have been shown to contain a KDEL sequence and
utilize the COPI-dependent pathway (16-18). There are, however, a subset of
these protein toxins are still able to traffic to the ER when COPI trafficking is
disrupted. Little is known about this COPI-independent pathway (19, 20).
Proteins that proceed to the ER can exit the endomembrane system.
Export from the ER to the cytosol can occur through one of two pores
located on the ER membrane: Sec61 (21-27)and/or Derlin-1 (28). The Sec61
protein complex is the main translocon utilized during co-translational
translocation of proteins into the endomembrane system. Most of these proteins
are destined for secretion. Ribosomes bind the mRNA and translation of the
proteins begins. Translation results in an N-terminal signal sequence. A signal
recognition protein (SRP) binds to the ribosome and the translated signal
sequence halting translation of the protein. The ribosome-SRP complex binds to
an SRP receptor located on the ER membrane, which transfers the ribosome to
the Sec61 translocon. Transfer to the Sec61 translocon allows release of the
SRP and SRP receptor and protein translation resumes into the ER lumen.
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Immediately upon entering the ER the newly synthesized protein undergoes a
number of post-translational modifications. The signal sequence is cleaved and
glycosylation occurs to help promote proper folding and assembly. If the proteins
are unable to fold properly they are exported back through the Sec61 translocon
through a process called ER associated degradation (29). Recent evidence has
revealed that a second pore is capable of retro-translocation. Over expression of
a dominant-negative Derlin-1 inhibited the ER to cytosol transfer of the catalytic
subunit of cholera toxin (CTA1), suggesting Derlin-1 is responsible for CTA1
retro-translocation (28).

1.2 ER-Associated Degradation
The ER is the site for folding and packaging of proteins destined for
secretion or residence within the endomembrane system. As proteins are cotranslationaly translocated across the ER membrane, several covalent
modifications take place. These modifications are a part of the quality control
system within the ER to ensure proper folding and organelle distribution. The ER
also contains numerous molecular chaperones that serve to correct non-native
conformations. BiP is a member of the Hsp70 family that recognizes misfolded
proteins by binding to hydrophobic amino acid sequences that are normally
buried in properly folded proteins (30). ER DNA J homologue proteins (ERdj)
serve to stimulate the function of BiP (31). Protein disulfide isomerase (PDI)
helps to form disulfide bonds by catalyzing the oxidation and isomerization of
sulfhydryl groups on cysteines (32). Calnexin and calreticulin are lectins that
bind to monoglucosylated N-linked oligosaccharides that occur after removal of
4

glucose residues by ER glucosidases. ERp57 interacts with the calnexin- or
calreticulin-bound proteins to generate disulfide bonds (33, 34). Glucosidase II
removes the final glucose from the protein. If the protein is correctly folded,
glucosyltransferases (GT) will not be able to add glucose sugars to the protein
and it can be exported from the ER. In the event that the protein is incompletely
folded, the GT will add a glucose residue and return the protein to the
calnexin/calreticulin cycle in an effort to fold the protein properly (35). In the
event that the protein cannot attain a native conformation, the proteins are
selected for retro-translocation to the cytoplasm where they can be degraded by
the 26S proteasome. Terminally misfolded proteins are targeted to the Sec61
and/or Derlin-1 pores by a complex of BiP and at least one HSP40 cochaperone, HEDj or ERdj3 (36). Upon export from the ER lumen, the misfolded
proteins are ubiquitinated. The 19S cap of the proteasome recognizes the
ubiquitinated proteins and further unfolds the proteins for degradation by the 20S
proteasomal core (37).

1.3 AB Type Protein Toxins
Plants and bacteria utilize a number of protein toxins for cytotoxic or
cytopathic activity in mammalian cells. One group of these protein toxins is
referred to as AB-type protein toxins. This group of toxins includes: cholera toxin
(CT), Ricin, Shiga toxin, exotoxin A (ETA), pertussis toxin, diphtheria toxin (DT)
and anthrax toxin. These toxins are characterized by their catalytic A subunit
and their cell binding B subunit. AB-type protein toxins bind to a wide assortment
of cell receptors and utilize multiple endocytic pathways(38-40). These toxins
5

attack a wide array of cytosolic targets with various enzymatic activities. The one
thing all these toxins have in common is that they all bind to the extracellular
surface of mammalian cells and must find a way to translocate across a
membrane to reach their cytosolic targets. AB protein toxins bind to the cell
surface and are internalized by varying endocytic mechanisms. DT and the
anthrax toxins are able to escape the endosomal compartment by virtue of pHinduced conformational rearrangement that allows these toxins to create their
own pore within the endosomal membrane (41, 42). The other AB toxins listed
above are trafficked to the ER (42-45). Upon arrival in the ER, the A subunit
dissociates, attains a conformation that mimics a misfolded protein, and is
targeted by ERAD for retro-translocation out of the ER. As previously mentioned,
ERAD substrates are ubiquitinated and targeted to the proteasome for
degradation (46). Ubiquitination occurs on lysine residues. AB toxins are
capable of avoiding proteasomal degradation due to their lysine deficiency in the
A subunits (47). Now released from the ER membrane system and unaffected
by proteasomal degradation, the toxins are free to attack their cytosolic target.
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1.4 Models for Translocation
As previously stated, the problem shared by all AB toxins is the necessity
for traversing the organelle membrane barrier for intoxication. DT and anthrax
toxin are able to escape the endosomal membrane system with pH-induced
alterations in protein structure that allow the toxins to create their own pore to the
cytosol. The other listed toxins are not capable of self-translocation and must
rely on pores already in existence within the cell. There is only one location in
the endomembrane system that contains pores capable of allowing exit for the
toxins, which is the ER. The toxins travel in a retrograde fashion to the ER where
they masquerade as misfolded proteins to utilize the ERAD system for export to
the cytosol (48, 49). CT escape from the ER requires: reduction of the disulfide
bond between the A1 and A2 subunits, disassembly of the holotoxin into CTA1
and CTA2-CTB, and unfolding of the A1 subunit into a translocation-competent
state. Reduction the disulfide bond occurs when the holotoxin arrives in the ER.
Although the conditions of the ER are normally suited for disulfide bond
formation, the GSH/GSSG ratio within the ER is capable of reducing the disulfide
bond that bridges CTA1 and CTA2-CTB (50). PDI then facilitates the
disassembly of the reduced holotoxin.
It has been reported that PDI also plays a role in the active unfolding of
the CTA1 subunit (51). The previous model for CT translocation suggests that
the holotoxin is reduced in the ER, and PDI unfolding of holotoxin-associated
CTA1 is what dislodges CTA1 from the holotoxin. An alternate model presented
here suggests that CT is reduced in the ER and that PDI mediates dissociation of
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the CT subunits. This model was based solely on an indirect biochemical
experiment using the cleavage of CTA1 by trypsin (51). The trypsin cleavage
assay is an in vitro assay where a protein is treated with trypsin to determine its
folding state, because unfolded proteins should be cleaved more readily. By this
(51) assay PDI was shown to make CTA1 more vulnerable to trypsin. The
unfoldase activity of PDI has been largely the subject of debate. We believe that
PDI serves only to dislodge the CTA1 from the rest of the toxin and that it does
not actively unfold CTA1. In contrast to the original model, we have shown that
CTA1 is a thermally unstable protein and that dissociation from the rest of the
holotoxin allows spontaneous unfolding of CTA1 (56‐58). Here, we will
demonstrate using direct biophysical measurements that PDI does not unfold
CTA1; it only removes CTA1 from the A2/B portion of the toxin. CTA1 is
thermally instability is responsible solely for its translocation competence and if
that was stabilized it could halt progression out of ER.
We predict stabilized CTA1 will not be recognized as a misfolded protein
by ERAD and will be unable to exit the ER, thus preventing intoxication. We
predict that a chemical chaperone 4-phenylbutyrate (PBA) will stabilize CTA1
within the ER and will block unfolding and translocation into the cytosol. The
inability of CTA1 to reach the cytosol will ultimately block intoxication. Not only
must the toxin achieve a translocation competent state, but it must also be
actively extracted from the ER.
The original model of CTA1 translocation mentioned before stated that
CTA1 is stable and must be actively unfolded and delivered to Derlin-1 for
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translocation. It would refold as soon as it proceeded through the pore,
extracting itself through what is called the molecular ratchet. With this model,
CTA1 will begin to refold as soon as it emerges at the cytosolic face of the ER
membrane. The refolding will not allow it to return back into the ER pore.
Because CTA1 is thermally unstable and unfolds at physiological temperatures
the molecular ratchet model doesn’t work. CTA1 must actively be dislocated out
of the ER into the cytosol. CTA1 must also refold and maintain a folded
conformation in order to act on its target. There must be a cytosolic protein or
complex that is responsible for the extraction to CTA1 from the ER into the
cytosol. Hsp90 is a folding chaperone that has been shown to be associated
with the cytosolic lumen of the ER. We show that Hsp90 binds to CTA1 very
tightly invitro. We hypothesize that Hsp90 is involved in the extraction of CTA1
out of the ER into the cytosol. Blocking the interaction of Hsp90 and CTA1
should block intoxication if it is indeed responsible for CTA1 dislocation.
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CHAPTER 2 MATERIALS AND METHODS

2.1 Chemicals and Reagents
Sigma Aldrich (St. Louis, MO)
Calcium Chloride (CaCl2)
Ethylenediaminetetraacetic Acid (EDTA)
Leupeptin
N-ethyl maleimidie (NEM)
Niaproof-4 (NP-40)
Pepstatin
Phenymethylsulfonyl Flouride (PMSF)
Potassium Chloride (KCl)
Protease Inhibitor Cocktail
Protein A
Tetramethylethylenediamine (TEMED)
Thermolysin
Trichloroacetic Acid (TCA)
Fisher Scientific (Pittsburgh, PA)
2-Mercaptoethanol (β-ME)
Deoxycholic Acid
Ethanol 200 proof (EtOH)
Gel Code Blue Stain Reagent
Glycerol
Hydrochloric Acid (HCl)
Magnesium Cholride (MgCl2)
Methanol (MeOH)
Sodium Acetate (NaCH3COO)
Sodium Chloride (NaCl)
Sodium Hydroxide (NaOH)
Sodium Phosphate Dibasic Anhydrous (Na2HPO4)
Sodium Phosphate Dibasic Heptahydrate (Na2HPO4·7H2O)
Sodium Phosphate Monobasic Anhydrous (NaH2PO4)
Sodium Phospate Monobasic Monohydrate (NaH2PO4·H2O)
Tris Base
Tryptone
Tween-20
Invitrogen (Carlsbad, CA)
Antibiotic-Antimycotic
Dulbecco’s Modified Eagle Medium (DMEM)
Geneticin
Ham’s F-12
10

Lipofectamine
Trypsin/EDTA
Amresco (Solon, OH)
Ammonium Persulfate (APS)
Bromophenol Blue
Glycine
HEPES
Methionine
Sodium Dodecyl Sulfate (SDS)
Tris-Cl
Triton X-100
Calbiochem (La Jolla, CA)
Adenodine Triphosphate (ATP)
Digitonin
Bio Rad (Hercules, CA)
40% Acrylamide /Bis Solution
Extra Thick Filter Paper
BostonBiochem (Cambridge, MA)
20S Proteasome
Beckman Coulter (Fullerton, CA)
Scintillation Fluid
Perkin Elmer (Waltham, MA)
[35S] Methionine
Alpha Biosciences (Baltimore, MD)
Yeast Extract
Atlanta Biologicals (Lawrenceville, GA)
Fetal Bovine Serum
Millipore (Billerica, MA)
Immobilin (PVDF)
BD Biosciences (San Jose, CA)
Skim Milk
GE Healthcare (Piscataway, NJ)
BioTrak [125I] cAMP Assay Kit
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2.2 Toxins
List Biological Laboratories (Campbell, CA)
Cholera Toxin, Holotoxin
Calbiochem (La Jolla, CA)
Cholera Toxin, A subunit
2.3 Antibodies
Stressgen (Ann Arbor, MI)
Rabbit α-Hsp90
Rabbit α-PDI
Sigma Aldrich (St. Louis, MO)
Rabbit α-CTA
Jackson Immunoresearch (West Grove, PA)
Goat anti-Rabbit IgG conjugated to HRP
2.4 Equipment
Bio Rad (Hercules, CA)
Bio Rad Power Pac Basic
Bio Rad Power Pac HC
Model 853 Gel Dryer
Trans-Blot SD Semi-Dry Transfer Cell
Beckman Coulter (Fullerton, CA)
LS 6500 Multi Purpose Scintillation Counter
Wallack
Gamma Counter
GE Healthcare (Piscataway, MJ)
Äkta purifier
Storm 840 Phospho-Imager
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BioTek Instruments (Winooski, VT)
Synergy 2 Plate Reader
Jasco (Tokyo, Japan)
4200 FTIR Spectrometer
2.5 Other Materials
Grenier Bio One
6-well flat-bottom tissue culture plates
24-well flat-bottom tissue culture plates
96-well black, flat-bottom tissue culture plates
GE Healthcare (Piscataway, MI)
GSTrap HP (GST glutathione column)
American Type Culture Collection
Chinese Hamster Ovary (CHO) cells
HeLa cells
Vero cells
Invitrogen (Carlsbade, CA)
d2eGFP plasmid
pcDNA 3.1 plasmid
2.6 Buffers
Phosphate Buffered Saline (PBS), 10x
82.3 g Na2HPO4 (0.58M)
23.5 g NaH2PO4 (0.17M)
40 g NaCl (0.69M)
H2O to 1 liter
Tris-Buffered Saline (TBS), 10x
24.24 g Tris-Cl
5.56 g Tris Base
80.1 g NaCl
H2O to 1 liter
Transfer Buffer
100 ml 10x SDS-Electrophoresis Running Buffer
200 ml MeOH
600 ml H2O
SDS-Electrophoresis Running Buffer, 10x
30.2 g Tris Base
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144 g Glycine
10 g SDS
H2O to 1 liter
SDS sample buffer, 4x
50 ml 4x Tris-Cl/SDS pH 6.8
40 ml Glycerol
8 g SDS
2 mg bromophenol blue
100 mM 2-mercaptoethanol (7µl of 14.3 M ß-ME /ml of 4x buffer)
Lysis Buffer
25 mM Tris-Cl pH 7.4
20 mM NaCl
1% Deoxycholic Acid
1% Triton X-100
1 mM Phenylmethylsulfonyl fluoride (PMSF)
1 µg/ml Pepstatin
1 µg/ml Leupeptin
NDET
1% NP-40
0.4% Deoxycholic Acid
5 mM EDTA
10 mM Tris-Cl, pH 7.4
150 mM NaCl
Sodium Phosphate Buffer, 0.1 M
Solution A: 27.6 g NaH2PO4·H2O per liter (0.2 M)
Solution B: 53.65 g Na2HPO4·7H2O per liter (0.2 M)
100 ml of pH 7.0 buffer add 39.0 ml of solution A and 61 ml of solution B
HCN Buffer
50 mM HEPES, pH 7.5
150 mM NaCl
2 mM CaCl2
10 mM N-ethyl maleimide (NEM)
1:20 dilution of Protease Inhibitor Cocktail
20S Proteasome Assay Buffer, 2x
100 mM HEPES, pH 7.5
20 mM MgCl2
200 mM KCl
0.2 mM CaCl2
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GST Protein Purification Buffer
100 mM KCl
20 mM Tris-Cl, pH 7.5
5 mM MgCl2
LB Broth
10g Tryptone
5 g Yeast Extract
5 g NaCl
H20 to a liter
2.7 Tissue Culture
Cells seeded to a 10 cm dish were washed once with Phosphate Buffered
Saline (PBS). 1 ml of trypsin-EDTA was added to the plate and incubated at
37°C for 5 minutes. 9 mls of the appropriate complete tissue culture media
(containing 10% fetal bovine serum (FBS) (Atlanta Biological Lawrenceville, Ga.)
and 1% antibiotic-antimycotic (Invitrogen Carisbad, CA.)) was added to the plate
and titurated to resuspend the cells. CHO cells require Ham’s F-12 (Invitrogen);
and HeLa require Dulbecco’s Modified Eagle Medium (DMEM) (Invitrogen). 9 mls
of complete media was added to a new 10 cm dish and 1 ml of the cell
resuspension was added to the new 10 cm dish. The seeded dish was rocked
back and forth to ensure even distribution of the cells on the plate. When the
cells reached 80% confluency on the 10 cm dish, they were again split.
Variations of the above protocol were used for alternate incubation times
and for seeding to alternate plates. The dilution of 1 ml cell resuspension to 9 ml
complete media reached 80% confluency after 3-4 days of incubation at 37°C. A
dilution containing 0.5 ml of cellular resuspension and 9.5 ml of media was often
used to extend the incubation of cells to 4 days. For incubation times greater
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than three days, the media was removed and replaced with 10 ml of fresh media.
Cells that were seeded into a 6-well plate required a dilution of 1 ml cellular
resuspension to be added to the well along with an additional 0.5 ml of media.
Cells seeded into 6-well plates at this dilution reached 80% confluency in 18-24
hours. Cells that were seeded to 24-well plates required a dilution of 1 ml of
cellular resuspension to be mixed with 5 ml of complete media. 0.5 ml of the
1:5.5 dilution was added to each well of a 24-well plate for use after an overnight
incubation.

2.8 Transfection
CHO cells were seeded to a 6-well plate and grown to 80% confluency
following an overnight incubation at 37°C. Following the incubation transfection
mixtures were prepared in eppendorf tubes. Solution A was placed in one tube
consisting of 1 µg of DNA per 100 µl of serum-free media. Solution B was placed
in a separate tube consisting of 5 µl of Invitrogen lipofectamine reagent per 100
µl of serum-free media. Solution A and solution B were then combined and
incubated at room temperature for 30 minutes. The cells were washed with 2 ml
of serum-free media to remove any residual media the cells were seeded in.
One ml of serum-free media was added to each well followed by 200 µl of the
DNA/lipofectamine transfection mixture. Following a 3 hour incubation at 37°C,
the transfection mixture was removed, the cells were washed with antibiotic- and
serum-free media, and 1.5 ml of serum-free media was added for overnight
incubation at 37°C. Co-transfection assays in CHO cells consisted of 1 µg of
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DNA for each plasmid per 100 µl of serum-free media. Solution B remained the
same.
For transfection of HeLa cells solution A consisted of 0.5 µg DNA per 100 µl
of serum-free media, and solution B consisted of 8 µl of lipofectamine per 100 µl
of serum-free media. HeLa cells were incubated with transfection mixture for 5
hours at 37°C. All other steps were identical to the above protocol for
transfection of CHO cells.

2.9 Toxicity Assay – cAMP
Cells were seeded into flat-bottom 24 well plates and grown overnight to
80% confluency (in triplicate). The media was removed and replaced with
serum-free media containing the various concentrations of CT in the absence or
presence of drug treatments. After a 2 hour incubation the cells were washed
with PBS, and 0.25 ml of ice cold HCl:EtOH (1:100) was added for 10 minutes at
4°C or on ice. The liquid was removed, placed in microcentrifuge tubes and
allowed to air dry. cAMP levels were then determined using a (Perkin Elmer
Waltham, MA) [125I] cAMP competition assay kit as per the manufacturer’s
instructions. The values obtained were then background subtracted from cells
that were treated with no toxin. The maximum response was arbitrarily set to
100%, and all other values were expressed as a ratio of that value.
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2.10 Translocation Assay
HeLa cells were seeded to 6-well plates in complete DMEM media to
achieve 10,000 cells/well after an overnight incubation at 37°C. Triplicate wells
were required for each condition. Following the overnight incubation, the media
was replaced with serum-free, antibiotic-antimycotic free DMEM (DMEM Only)
media containing 100 ng/ml of GM1 and incubated at 37°C. After a 1 hour
incubation, the media was replaced with 1 ml of DMEM only containing 1 µg/ml of
CT and placed at 4°C. After a 30 minute incubation, the media was removed and
the cells were washed with PBS prior to being lifted from the 6-well plate using
750 µl of 0.5 mM EDTA in PBS per well. Three wells for each condition were
added to a single microcentrifuge tube and spun at 5,000 x g for 5 minutes. The
supernatant was discarded and the pellet was resuspended in 0.04% Digitonin in
HCN buffer and placed on ice for 10 minutes. The samples were spun at 16,000
x g for 10 minutes, and the supernatant was collected and placed in a fresh
microcentrifuge tube. Samples to be analyzed by Western blot analysis received
120 µl of 1x sample buffer to the pellet fraction and 20 µl of 4x sample buffer to
the supernatant fraction. The samples were run on 15% sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) gels for electrophoresis.
Samples to be analyzed by surface plasmon resonance (SPR) received HCN
buffer to 1 ml. Samples for the co-transfection translocation assays were
resuspended to a volume of 1 ml in lysis buffer after the final centrifugation step.
These samples were pre-cleared with protein A sepharose beads. Following an
overnight incubation at 4°C, the samples were spun at 5,000 x g for 5 minutes.
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The supernatants were removed and placed into new centrifuge tubes for
immunoprecipitation.

2.11 Western Blot Analysis
Twenty five microliters of sample were loaded to a 15% SDS-PAGE gel.
The samples were allowed to run at 200 Volts for 60 minutes. Gels were washed
2 times in water and then equilibrated in transfer buffer for 10 minutes along with
2 pieces of filter paper. PVDF membrane was placed in MeOH for 10 seconds
and then transfer buffer for 10 seconds for activation. One piece of filter paper
was placed on the bottom platinum anode of the BioRad transfer apparatus
followed by the activated membrane then the equilibrated gel and the second
piece of filter paper. Air bubbles were rolled out prior to securing the top cathode
and safety cover. The transfer was conducted for 20 minutes at 10 Volts and
then 40 minutes at 15 Volts. The membrane was then incubated overnight at
4°C in 1% milk in TBS-T with primary antibody (rabbit α-HSP90 1:20,000; rabbit
α-PDI 1:5,000; rabbit α-CTA 1:20,000). After incubation the membrane was
washed in 1% milk in TBS-T for 5 minutes. The membrane was then incubated
at RT for 30 minutes with secondary antibody (rabbit IgG conjugated Horseradish
Peroxidase 1:20,000). Following incubation the membrane was washed once in
1% milk for 5 minutes and once in TBS-T for 5 minutes. ECL Plus Western
blotting detection reagents were used for detection following manufacturers
suggested protocol.
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2.12 Immunoprecipitation
Cells were seeded to 6-well plates and transfected as previously
described in triplicate. Cells were transfected with an empty vector (pcDNA 3.1),
mCTA1 plasmid or ssCTA1 plasmid (52). Following an overnight posttransfection incubation, the cells were incubated for 1 hour at 37°C in 0.5 ml of
methionine-free media. The cells were then washed with PBS and incubated for
1 hour at 37°C in 0.5 ml of methionine-free media containing 75 μCi [35S]
methionine. The cells were washed with PBS and lifted from the wells with 750
μl of 0.5 mM EDTA in PBS and placed into separate microcentrifuge tubes. The
tubes were centrifuged at 5,000 x g for 5 minutes. The supernatant was
discarded and the cell pellet was resuspended in 100 μl of 0.04% digitonin in
HCN buffer and placed on ice for 10 minutes. The samples were then spun at
16,000 x g for 10 minutes and the supernatant (i.e. cytosolic fraction) was
collected and placed into a separate microcentrifuge tube. 1 ml of lysis buffer
was added to the pellet (i.e. membrane fraction) and 900 μl of lysis buffer was
added to the supernatant fraction. Following incubation at 4°C for 20 minutes, 3
μl of anti-CTA antibody was added to each 1 ml fraction and incubated on a
rocker at 4°C. Following an overnight incubation, 30 μl of a protein A slurry
prepared by the manufacturer’s protocol was added to each fraction and
incubated on a rocker at 4°C. Following a 2 hour incubation, the samples were
centrifuged for 5 minutes at 5,000 x g. The pelleted beads were washed 2 times
with 1 ml NDET and once with 1 ml of water. 50 μl of 1X sample buffer was
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added to each pellet. The samples were run on a 15% SDS-PAGE gel and dried
to filter paper using a Bio Rad (Hercules, CA) gel dryer. The dried gels were
placed in a PhosphoImager cassette for 4 days and analyzed using a Storm 840
Phospho-Imager and Image Quant software (Sunnyvale, CA.). Background was
subtracted from all samples prior to data calculations. Percentage of cytosolic
CTA1 was defined as the supernatant divided by pellet plus supernatant (%
cytosol = sup/[pellet+sup]).

2.13 SPR Sensor Slide Generation
Gold-plated glass slides with a self-assembled monolayer, purchased from
Reichert (Depew, NJ), were activated by perfusing an EDC-NHS activation buffer
for 10 minutes. The activated plate was then washed for 5 minutes with PBS
(pH7.4) containing 1% Triton X-100 (PBST). Antibody was perfused over the
activated sensor slide at a dilution of 1:2,000 in PBST for 15 minutes. Unbound
antibody was washed off the sensor slide with a 5 minute PBST wash.
Ethanolamine was perfused over the sensor slide for 3 minutes to cap any
unbound tethers on the gold plated plate. All perfusions were at a flow rate of 5
μl/min

2.14 SPR Analysis
PBST was perfused over the antibody bound sensor slide for 5 minutes to
establish a baseline reading. Experimental samples were perfused over the antibody bound sensor slide. Following each experimental condition, bound ligand
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was removed from the sensor slide by washing the slide with PBST at pH 6.0.
Reichert Labview software was used for data collection.
The cytosolic pools generated were diluted in HCN buffer to a volume of 1
ml. For the translocation assays, the 100 μl sample generated from the digitonin
permeabilization was too small to run through the SPR instrument. CTA1
standards were diluted in HCN buffer for the translocation assay. Secretion
assays required all samples to be standardized to contain 5% glycerol in order to
eliminate any effects that glycerol might have on the detection by the SPR
instrument. CTA1 standards were therefore diluted in 5% glycerol for the
secretion assays. All solutions were perfused over the sensor slide at a flow rate
of 5 μl/min.

2.15 SPR Holotoxin Slide Generation
Gold sensor slides were purchased from Reichert. These sensor slides were
treated with a GM1 solution at a concentration of 1 mg/ml. This solution was
allowed to air dry at room temperature. CT was added in a PBS solution at
1ug/ml for 1 hour. The plate was then blocked with BSA at a 20 ug/ml
concentration for 1 hour.

2.16 SPR Holotoxin /PDI Dissociation
Plates were equilibrated with PBS-T at pH 7.4 for 5 to 10 minutes. Reduced PDI
was then injected at a concentration of 1 ug/ml. After a loss of mass was
recorded and a new base line has been recorded, a monoclonal antibody against
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CTA1 was added at 1:500 dilution in PBS-T. A PDI antibody followed the CTA1
antibody at a dilution of 1:10000. The next antibody that was flowed over the
slide was either a KDEL antibody at 1:10000 or a CTB antibody at 1:15000.

2.17 Fourier Transform Infrared Spectroscopy
Protein samples were prepared in D2O buffer containing 10 mM sodium borate
(pH 6.6). The samples contained either unlabelled PDI or 13C- labelled CTA1 or
both in a 1:1 molar ratio. FTIR experiments were carried out on a Jasco 4200
FTIR scectrometer at 0.964 cm-1 spectral resolution. The absorbance was
calculated using the respective buffers as a refrence and corrected by the
subtraction of H20 vapor contribution. Curve fitting was evaluated in the amide 1
region from second derivative spectra.
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CHAPTER 3 THE EFFECT OF PDI ON CT DESTABILIZATION
AND TRANSLOCATION
3.1 Introduction
It was accepted that only the reduced form of PDi would interact with the A
subunit of cholera toxin (53, 54). Reduced PDI was originally proposed to unfold
CTA1 subunit while it wa in association with the holotoxin. This unfolding is what
thereby promote the separation of CTA1 from the rest of the holotoxin (51). PDI
was also linked to the delivery of CTA1 to the translocon pore Derlin-1 (28, 55).
CTA1 was released to the Derlin-1 throught the oxidation of PDI by Ero1p (56). It
is in this manner that it was stated that PDI is a redox-dependant unfoldase of
CTA1.
3.2 CTA1 does not require PDI in order to become translocation competent
Recent structural studies, done by the Teter Lab, have indicated that CTA1
will unfold spontaneously after dissociation from the holotoxin at physiological
temperature (57-59). With this information It is no longer necessary for PDI to
actively unfold CTA1 and therefore unlikely. It is more likely that PDI has a more
minimal role in intoxication.

3.3 PDI interacts with CTA1
According to the original model of translocation, PDI must bind tightly to
CTA1 in order to unfold and then deliver CTA1 to the translocon. Direct binding
studies using SPR indicate that PDI does bind to CTA1 directly (Fig 3-1).
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Binding studies were carried out under conditions that mimic CTA1 structure in
association with the holotoxin. It is expected that PDI will interact with CTA1 in
the holotoxin. Two conditions that are known to stabilize CTA1 as it it is
stabilized in association with the holotoxin are acidic pH and 10% glycerol (5658). PDI binds CTA1 under stabilizing conditions but not under physiological
conditions. Unlike the previous model where PDI would delivers an unfolded
CTA1 to the translocon, PDI could not bind an unfolded CTA1 (Fig. 3-1). PDI
readily binds the folded conformation of CTA1, but can no longer bind with a loss
of CTA1 structure. Because CTA1 will unfold after separation from CTA2/CTB5,
and because PDI cannot remain bound to unfolded CTA1 it is unlikely that PDI is
responsible for delivery of CTA1 to the translocon.
PDI will interact with CTA1 in the holotoxin when PDI is in the reduced state
(Fig. 3-2). The idea that CTA1 is stabilized in association with the holotoxin has
been well established (44-45) and is likely the reason for the misconception that
CTA1 is stable at physiological temperatures. PDI will bind only to the A subunit
of the holotoxin and then only to its folded conformation (Fig. 3-2). When
reduced PDI binds to CTA1 in the holotoxin robust binding occurs followed by a
distinct drop in signal by SPR. This loss of signal represents a shift in refracted
light that reflects a loss of mass from the sensor slide. The amount of mass lost
from the sensor slide represents much more mass than the amount of PDI that
was bound to the slide (Fig. 3-2). The loss of mass also may be coming from the
sensor slide itself. Antibody controls of CTA1, CTB, and KDEL distinctly show
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that the A1 subunit of CT is being removed by the interaction of reduced PDI and
CTA1.
The holotoxin plates are bound to the SPR plate by GM1. CTA1 antibody
shows that CTA1 is no longer present on the plate after exposure to reduced
PDI, while CTB and KDEL antibodies show that the B-pentamer and A2 linker
are both still present on the sensor slide (Fig. 3-2b). The PDI antibody shows
that PDI is also being lost from the plate, indicating that PDI is binding to CTA1
(Fig 3-2b). Stabilization of CTA1 using low pH or low temperature did not block
the activity of PDI in dissociation of CTA1 (Fig. 3-3). The previous model that
required PDI unfolding of CTA1 in order to dissociate it from the holotoxin, are
shown to be inaccurate in this figure. CTA1 can be stable and still be dissociated
from the holotoxin. Another part of that model stated that PDI delivers CTA1 to
the translocon. To address this, a SPR plate was created with CT holotoxin
bound by an antibody against the A subunit. When this antibody-bound holotoxin
plate was treated with reduced PDI, dissociation occurred as before (Fig. 3-4). In
this case when dissociation occurs the CTA1 subunit is left on the plate. If PDI
remains with the freed CTA1subunit in order to deliver it to the translocon, then
PDI should stay bound to CTA1 on the SPR plate. This was not the case. The
antibody controls show that PDI is no longer on the plate after holotoxin
disassembly, so PDI and CTA1 travel separately after the dissociation event.
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Figure 3-1 Binding of reduced PDI to CTA1
CTA1 unfolding displaces toxin-bound PDI. (A-B) Reduced PDI (PDI + 1 mM
GSH) was perfused over a CTA1-coated sensor slide at 37°C in pH 6.5 buffer.
After 250 sec, the pH of the perfusion buffer was either (A) maintained at pH 6.5
or (B) shifted to pH 7.0. PDI was present in the perfusion buffer throughout the
experiment. (C-D) Reduced PDI (PDI + 1 mM GSH) was perfused over a CTA1coated sensor slide at 37°C in buffer containing 10% glycerol. After 250 sec,
glycerol was either (C) maintained or (D) removed from the perfusion buffer. PDI
was present in the perfusion buffer throughout the experiment.
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Figure 3-2 CTA1 dislocation assay
Dissociation of the CT holotoxin by reduced PDI. (A) The following ligands were
perfused over a CT-coated SPR sensor slide at 37°C: PDI, oxidized PDI (PDI +
1 mM GSSG), an anti-CTA antibody, an anti-CTB antibody, and an anti-KDEL
antibody. (B) After taking a baseline measurement corresponding to the mass of
the sensor-bound holotoxin, reduced PDI (PDI + 1 mM GSH) was perfused over
the CT-coated sensor slide at 37°C. PDI was removed 400 sec into the
experiment and replaced with sequential additions of anti-PDI, anti-CTA, and
anti-KDEL antibodies as indicated by the arrowheads.
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Figure 3-3 CT disassembly under conditions that prevent the unfolding of
CTA1
After appending CT to a GM1-coated sensor slide, a baseline measurement
corresponding to the mass of the bound holotoxin was recorded. Reduced PDI
(PDI + 1 mM GSH) was then perfused over the CT-coated sensor at either (A)
37°C in pH 6.5 buffer or (B) 10°C in pH 7.0 buffer. PDI was removed 400 sec
into the experiment and replaced with sequential additions of anti-PDI, anti-CTA,
and anti-KDEL antibodies as indicated by the arrowheads. In panel A, an antiCTB antibody was also perfused over the slide as indicated by the final
arrowhead.
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Figure 3-4 CTA1 Association of PDI with CTA1 after holotoxin disassembly
CT was appended to a SPR sensor slide coated with a polyclonal anti-CTA
antibody, and a baseline measurement corresponding to the mass of the bound
holotoxin was recorded. Reduced PDI (PDI + 1 mM GSH) was then perfused
over the CT-coated sensor at 37°C. PDI was removed from the perfusion buffer
400 sec into the experiment and replaced with sequential additions of an anti-PDI
antibody, an anti-CTB antibody, an anti-KDEL antibody, and an anti-CTA
monoclonal antibody as indicated by the arrowheads. An identical result was
obtained when CT was initially appended to a sensor slide coated with the
monoclonal anti-CTA antibody and later detected with the anti-CTA polyclonal
antibody.
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3.4 Effect of PDI on CT Toxicity
If CTA1 unfolds by itself, then what role if any is PDI playing in intoxication?
PDI has been shown to remove the A1 subunit from the holotoxin in the previous
experiments. PDI is also linked to the toxicity of CT. To address the link of PDI
to the toxicity of cholera toxin, we utilized PDI deficient cells (Fig. 3-5). The PDI
deficient cell lines stably produce small interfering siRNA that repress the
production of PDI. The PDI deficient cell lines are resistant to exogenously
applied CT (Fig. 3-5a). PDI deficient cell lines were not resistant to CTA1 that
was transfected directly into the ER (Fig. 3-5b). This result points out that when
CTA1 that is free in the ER has no need to interact with PDI. In contrast, CTA1
in the holotoxin requires PDI to remove it from the holotoxin within the ER. This
evidence along with the SPR data points to a more limited role of PDI in cholera
intoxication than previously suggested. The role of PDI in intoxication may now
be limited to dislodging CTA1 from the rest of the toxin, at which point CTA1 can
unfold itself.
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Figure 3-5 In vivo role of PDI in CT intoxication and CTA1 translocation
(A) Parental TZM cells, TZM 1-2 cells stably transfected with PDI siRNA, and
TZM 5-1 cells stably transfected with a non-specific control siRNA were exposed
to the stated concentrations of CT for 2 h. Toxicity was then assessed from the
rise in intracellular cAMP. The averages ± standard deviations of three
independent experiments with triplicate samples are shown. (B) TZM, TZM 1-2,
and TZM 5-1 cells were transfected with a plasmid encoding a CTA1 subunit
appended with an ER-targeting sequence. cAMP levels recorded at 3 h posttransfection were standardized to CTA1 expression levels, and the resulting data
were plotted as percentages of the control response from parental TZM cells.
The averages ± ranges of 2 independent experiments are shown. (C) TZM, TZM
1-2, and TZM 5-1 cells were transfected with a plasmid encoding a CTA1 subunit
appended with an ER-targeting sequence. CTA1 immunoprecipitated from the
membrane (P; pellet) and cytosolic (S; supernatant) fractions of metabolically
labeled cells were resolved by SDS-PAGE. The averages ± ranges of cytosolic
CTA1 calculated from 2 independent experiments are shown in the graph.
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3.5 Effect of reduced PDI on the folding state of CTA1
The claim of PDI being a CTA1 unfoldase is not only entrenched and
regularly cited, but was based on an indirect measure of the CTA1 folding state.
This indirect measure of folding state is a protease assay, which assumes that
the protease trypsin will cleave an unfolded protein more readily than a folded
protein. This assay was not performed at physiological temperature and does
not accurately represent the folding state of CTA1.
Direct measurements of folding were required to determine the folding state
of CTA1 in the presence of reduced PDI. Fourier transform infrared
spectroscopy (FTIR) was utilized for this end. Over a range of temperatures and
conditions reduced PDI was added specifically to identify any alteration to the
structure of CTA1 (Fig. 3-6, 3-7). The percentages of structure that were
collected from the FTIR experiments are presented in (Table 3-1).
CTA1 was labelled with 13C in order to shift its spectra 50 cm-1. This shift
was necessary so that the amide I region of CTA1 would not overlap with the
same region of PDI. With this tool it was possible to distinguish the structure of
CTA1 from the structure of PDI. The resulting data demonstrated that CTA1
does not lose its structure in the presence of reduced PDI. Compared to the loss
of structure with temperature alone, PDI does not cause the loss of CTA1
structure. With this evidence, PDI has lost all claim of being an unfoldase.
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Figure 3-6 Effect of reduced PDI on the folding state of CTA1
FTIR spectra were recorded for PDI (dashed line), 13C-labeled CTA1 (dotted
line), or a 1:1 molar ratio of PDI + 13C-labeled CTA1 (solid line). All
measurements were taken at 10°C with 1 mM GSH in the pH 7.0 buffer.
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Figure 3-7 The 10°C structure of CTA1 in the absence or presence of PDI
Curve-fitting (A, C) and inverted second derivatives (B, D) for the FTIR
spectrum of 13C-labeled CTA1 recorded in the absence (A, B) or presence (C, D)
of PDI are shown. In panels A and C, the dotted line represents the sum of all
deconvoluted components (solid lines) from the measured spectrum (dashed
line).
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% of CTA1 Structure
Condition

α-helix

β-sheet

irregular

other

10°C

37

48

7

7

10°C + PDI

36

48

8

9

30°C

28

36

25

11

30°C + PDI

27

35

27

11

37°C pH 6.5

23

32

34

11

37°C pH 6.5 +

28

29

36

8

21

13

51

16

PDI
37°C

TABLE 3-1 Calculations of cytosolic CTA1
From the deconvolution of the spectra of the FTIR experiments we compiled a
table that gives the percentage of CTA1 structure in the presence and absence
of PDI. We used this information to determine that PDI is not unfolding CTA1.
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3.6 Discussion
The role of PDI intoxication is limited to the dissociation of CTA1 while the
unfolding of the CTA1 subunit is spontaneous. The previous model of PDI-CT
interactions is based upon the results of a protease sensitivity assay. This
assay, which was thought to show that CTA1 shifts from a folded to an unfolded
conformation, in the presence of reduced PDI actually shows a difference in free
CTA1 and CTA1 in the holotoxin.

Direct biophysical analysis of the

conformation of CTA1 in the presence or absence of reduced PDI did not support
the interpretation of this indirect experiment. Our SPR and FTIR data collectively
demonstrate that PDI removes CTA1 from the rest of the holotoxin where CTA1
will then spontaneously unfold and displace PDI. Cell-based studies were used
to further evaluate the role of PDI in CT intoxication and CTA1 translocation.
These assays show that PDI is necessary for the intoxication with exogenously
added toxin. However, PDI is not needed for toxicity in cells expressing CTA1 in
the ER as seen in the PDI-deficient cell lines.
Direct evidence was needed to determine if PDI could act as an unfoldase.
To this end, FTIR was utilized to determine the folding state of PDI in the
presence and absence of reduced PDI. This is the first time a direct, biophysical
technique has been used to examine the interaction between PDI and CTA1.
FTIR analyses demonstrate that PDI does not act as an unfoldase. CTA1
structure in the presence of PDI is as stable if not more stable than alone. The
unfolding of CTA1 is solely due to its spontaneous unfolding at physiological
temperature.

37

CHAPTER 4 STABILIZATION OF CTA1 BLOCKS
TRANSLOCATION AND INTOXICATION
4.1 Introduction
CT binds to the cell surface receptor GM1, is endocytosed and trafficked to
the ER by retrograde vesicular transport (43, 60-62). In the ER, the holotoxin
dissociates into individual A and B subunits (50, 51, 63). The catalytic CTA1
subunit mimics a misfolded protein and is recognized by the ER quality control
mechanism, ERAD, and exported from the ER to the cytosol (64-67). The
molecular mechanisms of this export process are poorly characterized. The
current model for CTA1 translocation is that upon entry into the ER, PDI binds to
CTA1 and actively unfolds the toxin (51). In contrast, we conclude from our data
that the trigger for the CTA1 translocation event is a thermal denaturation that
occurs after CTA1 dissociates from the rest of the holotoxin. Previous work has
already demonstrated the temperature-dependent conformational instability of
the CTA1 subunit (58). According to our model, stabilization of the CTA1 subunit
will prevent translocation and subsequent intoxication. PBA is chemical
chaperone that stabilizes protein structure. Previous reports have indicated that
glycerol can provide resistance to CT (57). Glycerol, however, is a poor
candidate for a preventative or treatment for cholera intoxication because it is
very toxic itself to cells. Here we show that PBA prevents the temperaturedependent loss of CTA1 structure which blocks translocation and results in
resistance to intoxication. PBA is a FDA-approved ammonia scavenger, which is
used to treat urea cycle disorders. PBA is a prime candidate for a preventative
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or treatment for CT intoxication, because it is easily tolerated in children and
adults for oral ingestion.
4.2 Effect of PBA on CTA1 Translocation
Dr. Tuhina Banerjee of the Teter lab confirmed by circular dichroism that
100 uM PBA stabilizes CTA1 and prevents it from unfolding at 37°C. Our model
suggests that stabilization of CTA1 structure traps the protein in a conformation
not suitable for translocation. To test this model, we used a translocation assay
to monitor the distribution of CTA1 in the cytosol and ER of untreated or PBAtreated cells. HeLa cells were incubated on ice for 30 minutes in the presence of
1 μg/ml of CT. Cells were pulse-labeled with CT at 4°C, a temperature that
prohibits endocytosis. Unbound toxin was removed, and the cells were allowed
to incubate at 37°C for 2 hours in either in the presence or absence of PBA.
Digitonin was then used to selectively permeabilize the cells and separate the
cytosolic fraction from the membrane/organelle fraction. We selectively
permeablized control cells to ensure that we could detect PDI, an ER chaperone,
only in the membrane/organelle fraction. We also probed for Hsp 90, a cytosolic
protein that should only be found in the cytosolic fraction. The selective
permeabilization of control cells showed that PDI was localized only in the
membrane/organelle fraction and that Hsp 90 was localized only to the cytosolic
fraction (figure 4-1a). These controls confirmed that selective permeabilization
via digitonin can distinguish cytosolic proteins from membrane/organelle proteins.
There is a decrease in the cytosolic amount of CTA1 was detected in cells that
were incubated at 37°C for 2 hours in the presence of PBA then cells were
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incubated in the absence of PBA (figure 4-1b). These data demonstrating that
intoxication in the presence of PBA inhibited CTA1 translocation into the cytosol.
Western blot analysis revealed that CTA1 was reduced even in the presence and
absence of PBA demonstrates that CTA1 is being trafficked to the ER properly
(Fig. 4-2). Because the disulfide linkage of CTA can only be reduced in the
environment of the ER, this experiment demonstrating that PBA is not acting on
any step of toxicity before the ER (42-45). In order to address the separation of
CTA1 from the holotoxin we utilized the SPR based PDI dissociation assay in the
presence of PBA. Our results demonstrated that PBA does not block the activity
of PDI in dislodging CTA1 from the rest of the holotoxin (Fig. 4-3). Thus, the low
levels of CTA1 in PBA-treated cell did not result from a block of CT transport to
the ER or a block of holotoxin disassembly.
To address the question of how PBA is affecting the translocation of CTA1
out of the ER, we transfected cells with a construct of CTA1 that is expressed
directly in the ER and determined the progression of this construct out of the ER
is not deterred with the addition of PBA (Fig. 4-4). Because the CTA1 present in
this assay is being produced directly in the ER all trafficking up to this point is not
a contribution. Utilizing pulse labeling with 35S and a selective permeabilization
assay, following a two hour chase, with PBA present allows us to demonstrate
that PBA does not affect the translocation of unfolded PBA. There must be a
difference in the exogenously added toxin and the transfected toxin in the ER
that allows for this discrepancy. Dr. Banerjee from the Teter lab has determined
by CD that PBA cannot refold CTA1, but can stabilize the toxin in its folded
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conformation. It is likely then that PBA stabilizes CTA1 while still in association
with the holotoxin and never allows it to lose the amount of structure, needed to
be recognized as an ERAD substrate. In contrast, PBA cannot stabilize the
transfected toxin, which enters the ER co-translationally in an unfolded state.
This experiment demonstrated that PBA does not directly inhibit translocation
into the cytosol. With the determination of CTA1 being kept in its folded
conformation in the presence of PBA, how is the toxicity of CTA1 being affected?
As expected, CTA1 loses its toxicity without progression out of the ER to reach
its target (Fig. 4-5). PBA has been shown in this study to stabilize CTA1.
Stabilization is sufficient in the ER to block translocation and toxicity.
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Figure 4-1 SPR analysis of PBA inhibiting CTA1 translocation
PBA blocks the translocation of CTA1 into the cytosol. HeLa cells were
pulse-labeled at 4°C for 30 min with 1 mg / ml of CT. The cells were then chased
for 2 hr at 37°C in toxin-free medium that contained no additions, 100 mM PBA,
or 5 mg / ml of BFA. Selective permeabilization of the plasma membrane with
digitonin was used to partition cell extracts into separate membrane (pellet; P)
and cytosolic (supernatant; S) fractions. (A): Both fractions were probed by
Western blot to establish the distributions of cytosolic marker Hsp90 and ER
marker PDI. (B): An SPR sensor slide coated with an anti-CTA antibody was
used to detect the cytosolic pool of CTA1 from untreated (no treatment) or drugtreated cells. CTA standards (100, 10, 1, and 0.1 ng / ml) were perfused over the
sensor slide as positive controls; only the 1 and 0.1 ng / ml standards are shown
for scaling purposes. A cytosolic fraction from unintoxicated cells was also
generated for this experiment. One of three representative experiments is
shown. At the end of each experiment, bound sample was stripped from the
sensor slide.
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Figure 4-2 Effect of PBA on CT Transport to the ER
PBA does not prevent the reductive separation of CTA1 from CTA2. 1 mg
samples of the CTA1/CTA2 heterodimer were exposed to 10 mM β-ME for 5 min
in the absence or presence of 100 mM PBA before loading on a non-reducing
SDS-PAGE gel. 1 mg of a CTA1/CTA2 heterodimer that was not exposed to βME was also run on the gel. Samples were visualized by Coomassie staining,
which does not detect the dissociated 5 kDa CTA2 subunit
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Figure 4-3 Effect of PBA on dissembly of the CT holotoxin
PBA does not block the dissociation of CTA1 from CTA2/CTB5. After appending
CT to a GM1-coated SPR sensor slide, a baseline measurement corresponding
to the mass of the holotoxin was recorded. Reduced PDI was then perfused over
the slide in the presence of 100 mM PBA. PDI was present in the perfusion
buffer until approximately 500 sec into the experiment, after which it was
replaced with sequential additions of an anti-CTA antibody, an anti-PDI antibody,
and an anti-CTB antibody (arrowheads).
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Figure 4-4 Effect of PBA on CT Translocation
PBA does not inhibit the translocation of an ER-localized CTA1 construct. CHO
cells were transfected with a plasmid encoding a CTA1 subunit appended with an
ER-targeting signal sequence. Permeabilization of the plasma membrane with
digitonin was used to partition cell extracts into separate organelle (pellet; P) and
cytosolic (supernatant; S) fractions. (A): Both fractions from transfected cells
were probed by Western blot to establish the distributions of Hsp90 and PDI.
(B): The distribution of CTA1 immunoprecipitated from transfected cells after a 1
hr radiolabeling was visualized and quantified by SDS-PAGE with
PhosphorImager analysis. Experiments were performed with untreated cells and
cells exposed to mM PBA. The means ± SEMs of three independent
experiments is presented in the graph.
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Figure 4-5 Effect of PBA on CT Toxicity
PBA inhibits CT intoxication. (A): HeLa cells were incubated with CT in the
absence or presence of the stated PBA concentrations. After two hours of
continual toxin exposure, toxicity was assessed from the elevated levels of
intracellular cAMP
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4.3 Discussion
The previous model for CTA1 translocation suggests that the A subunit is
thermally stable and requires active unfolding in the ER to interact with the ERAD
machinery. It was originally thought that the trigger for this unfolding event was
the C-terminal hydrophobic region of CTA1 (49). However, recent work has
shown that the C-terminal region of the toxin is not necessary for translocation to
the cytosol (68). We propose that the trigger for ERAD is the thermal instability
of CTA1. Our model suggests that CTA1 dissociation from the holotoxin results
in the spontaneous unfolding of CTA1. Unfolded proteins are what the ERAD
machinery recognizes and eliminates from the ER. Based on this model we
predict that stabilization of the CTA1 structure would prevent translocation of the
toxin to the cytosol. Without an active A1 subunit of the toxin in the cytosol, there
would be no harmful effects from the endocytosed toxin.
PBA stabilization prevented CTA1 from reaching a translocation
competent state that could reach the cytosol. Inhibition of translocation resulted
in a decrease in toxicity. These effects reveal the importance of thermal
instability during the normal course of intoxication. The supposed trigger for
ERAD is not due to any particular domain of the toxin, but comes from a general
loss of structure. Stabilization results in a CTA1 that is not recognized as a
misfolded protein by ERAD. Without the aid of ERAD, CTA1 has no ability to
gain entry into the cytosol and will most likely be degraded in the endomembrane
system.
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4.4 Future Directions
Exposure to a chemical chaperone such as 10% glycerol was never a viable
therapeutic option. PBA, on the other hand, is a FDA-approved chemical
chaperone that will stabilize CTA1 in the ER and block translocation into the
cytosol. This suggests that PBA is a potential therapeutic for the treatment of CT
intoxication and possibly other AB toxins. Other ER-translocating toxins also
appear to have thermally unstable A chains, so the stabilization of these subunits
is a potential target for multi-toxin therapeutics. The next direction in this study
will be evaluating this drug for inhibition of other AB toxins. PBA will also be
studied in an animal model to test whether or not PBA can protect animals from
intoxication.
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CHAPTER 5 HSP90 IS REQUIRED FOR TRANSFER OF THE CHOLERA
TOXIN A1 SUBUNIT FROM THE ENDOPLASMIC RETICULUM TO THE
CYTOSOL
5.1 Introduction
The commonly cited method of CTA1 escape from the ER requires CTA1 to
refold itself on the cytosolic face of the ER (51). This refolding of CTA1 in the
cytosol is supposed to provide the driving force for extraction out of the ER.
Recent CTA1 structural studies do not support this model, because the isolated
CTA1 subunit will be unfolded at physiological temperature (57, 58, 69). Without
an innate stability, the molecular ratchet mechanism of self extraction is counterintuitive.
Most ERAD substrates are extracted from the ER through a pathway that
involves p97 (70). However, p97 has been determined not to play any role in
CTA1 dislocation (71, 72). Since CTA1 maintains an unfolded conformation at
37°C, some host protein must provide the driving force for CTA1 extraction from
the ER. This unidentified protein could possibly use refolding to drive the
extraction process. One possible candidate, Hsp 90 was observed to extract DT
from the endosomes to the cytosol. Hsp 90 has also been shown to maintain
membrane-bound ERAD substrates in a soluble state and to decide the fate of
these proteins. Finallly, Hsp 90 has been localized to the cytosolic face of the
ER.
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5.2 Hsp90 binds to CTA1
Hsp90 must bind directly to the A1 subunit of CT in order to be responsible
for CTA1 extraction out of the ER. To address this issue, SPR was used to
determine whether Hsp90 could directly interact with the isolated CTA1 subunit
at physiological temperature (Fig. 5-1). Hsp90 binding to CTA1 occurred in an
ATP-dependent manner that was blocked by geldanamycin (GA), a competitive
inhibitor of the ATP binding pocket. Hsp90 binds to CTA1 at 37°C. Since CTA1
is in an unfolded conformation at 37°C (22,24), this also suggested that Hsp90
identifies CTA1 as an unfolded protein. If Hsp90 is recognizing CTA1 as an
unfolded protein then it could be attempting to refold CTA1 during the dislocation
event. Because GA affects both Hsp 90 and Grp94 both GA and NECA,a drug
that only inhibits Grp 94, were used in order to differentiate whether any block in
toxicity was due to Hsp 90 or Grp 94. The interaction between CTA1 and Hsp90ATP was not substantially affected by NECA (Fig. 5-1). The interaction between
Hsp90 and CTA1 was much tighter than between GRP94 and CTA1 (Fig. 5-2
and Table 5-1). Consistent with the fact that both Hsp90 and GRP94 form
dimers (73), both chaperones bound to CTA1 in a 2:1 ratio of chaperone:toxin
(Fig. 5-2). The specific, high-affinity interaction between Hsp90-ATP and CTA1
indicated that Hsp90 could be involved with the CT intoxication process.
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Figure 5-1 Binding studies between CTA1 and Hsp 90
GA but not NECA inhibits the interaction between CTA1 and Hsp90. Either
Hsp90 (A) or GRP94 (B) was perfused over a CTA1-coated SPR sensor slide at
37°C under the following conditions: no ATP in the perfusion buffer, ATP in the
perfusion buffer, ATP and GA in the perfusion buffer, or ATP and NECA in the
perfusion buffer. Ligand was removed from the perfusion buffer 240 sec into the
experiment. One of four representative experiments is shown. In panel B, ***
indicates all experimental conditions other than GRP94 + ATP.
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Figure 5-2 Hsp 90 binding affinity to CTA1
Binding of CTA1 to Hsp90 or GRP94 (A): Hsp90 was perfused over a CTA1coated SPR sensor slide at 100, 400, 800, 1,600, and 3,200 nM concentrations.
The ligand was removed from the perfusion buffer after 115 sec. (B): GRP94 was
perfused over a CTA1-coated SPR sensor slide at 100, 200, 400, 800, and 1,600
nM concentrations. The ligand was removed from the perfusion buffer after 118
sec. Note that the results for Hsp90 and GRP94 are plotted on different scales.
For all conditions, ATP was present in the 37°C perfusion buffer. The orange
lines represent best fit curves derived from the raw data using 1:2 (CTA1:Hsp90
or CTA1:GRP94) binding models.
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CTA1 binding partner
Hsp90
GRP94

ka (1 / Ms)
9,929
1,537

kd (1 / s)
7.8 x 10-5
4.5 x 10-4

KD (nM)
7
292

TABLE 5-1 Calculations of cytosolic CTA1
CTA1 exhibits a high affinity interaction with Hsp90 and a lower affinity
interaction with GRP94. On rates (ka), off rates (kd), and equilibrium dissociation
constants (KD) between CTA1 and either Hsp90 or GRP94 were calculated from
the data presented in Figure 2.
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5.3 Hsp90 is involved in cholera intoxication
To detect a role for Hsp90 in CT intoxication, CT toxicity assays were
performed in the presence or absence of GA (Fig. 5-3). The elevated levels of
cAMP resulting from CT intoxication were strongly inhibited in GA-treated cells.
Whereas CT activity against untreated control cells exhibited a half-maximal
effective concentration at 4 ng CT / ml, GA-treated cells only produced a third of
the maximal cAMP response when they were treated with 100 ng CT / ml. Thus,
much more CT was be required to elicit the same amount of intoxication in GAtreated cells as compared to control cells. NECA-treated cells demonstrated the
same level of sensitivity to CT as the untreated control cells (Fig. 5-3). From this
we conclude GA-induced toxin resistance is not a result of the inactivation of
GRP94. To ensure that our drug for knocking down the activity of Grp94 was
active, we performed a control with NECA for ricin. NECA-treated cells were
resistant to ricin, another AB toxin that uses the ERAD system for A chain
dislocation to the cytosol. Control experiments demonstrated that GA did not
block the activity of CTA1 expressed directly in the cytosol of cells transfected
with a CTA1-encoding plasmid (52) (Fig 5-4). Furthermore, GA did not inhibit
forskolin, an adelyate cyclase agonist, from inducing elevation of cAMP. This
control demonstrated that GA did not directly inhibit the production of cAMP by
adenylate cyclase.
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Figure 5-3 CTA1 Toxicity assay with Hsp 90 inhibitor present
GA but not NECA inhibits CT intoxication. (A): CHO cells were incubated with
varying concentrations of CT in the absence of additional treatment, in the
presence of 0.1 μM GA, or in the presence of 0.1 μM NECA. After 2 hr of
continual toxin exposure, toxicity was assessed from the elevated levels of
intracellular cAMP. The means ± standard errors of the means (SEMs) of at least
four independent experiments with triplicate samples are shown.
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Figure 5-4 GA does not affect the activity of cytosolic CTA1
CHO cells were transfected with a plasmid encoding a CTA1 subunit that is
expressed directly in the cytosol. Intracellular cAMP levels were then calculated
at either 2 hrs (n = 1) or 4 hrs (n = 2) post-transfection for cells chased in the
absence or presence of 0.1 M GA. Triplicate samples were used for each
measurement.
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5.4 Hsp90 is responsible for the extraction of CTA1 out of the ER into the
cytosol
Toxin resistance can result from an inhibition of toxin progression out of the
ER to the cytosol (28, 66, 74). To determine if GA blocked toxin export to the
cytosol, we utilized a dislocation assay (57, 75) to monitor the arrival of CTA1 to
the cytosol (Fig. 5-5). GA-treated HeLa cells were protected from CT in their
cAMP production as they were in CHO cells. The control experiment
demonstrates that our selective permeabliization maintained the fidelity of
membrane contained fractions and cytosolic fractions (Fig 5-5a). Hsp 90 was
used as a cytosolic marker and PDI was a marker for membrane encased
soluble proteins. Western blot analysis detected little or no PDI in the
supernatant fraction. Western blot analysis using non-reducing conditions was
used to track the localization of CTA1 (Fig. 5-5b). The 21 kDa CTA1 subunit is
produced as part of a larger heterodimer. Proteolytic cleavage of CTA creates a
CTA1/CTA2 heterodimer, which has to be reduced in the ER. Only the smaller
reduced CTA1 is able to enter into the cytosol. Consisitent with this, our results
detected both disulfide-linked CTA1/CTA2 and reduced CTA1 in the membrane
fractions, but only found reduced CTA1 in the cytosol. NECA treatment did not
affect the distribution of CTA1 in the membrane bound fraction vs. the cytosolic
fraction. Treatment of cells with GA resulted in the accumulation of less cytosolic
CTA1 than untreated or the cells treated with NECA. It is thus apparent that
Hsp90 function was required for the progression of CTA1 from the ER into the
cytosol.
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SPR was utilized to quantify the actual amount of CTA1 that reached the
cytosol. HeLa cells were pulse treated with CT at 4°C and were again
fractionated into membrane contained and cytosol components after a 2 hour
chase at 37°C. The cytosolic fractions were introduced to a SPR sensor slide
that had been coated with a CTA antibody (Fig. 5-5c). There is a distinct
relationship between the association constant determined by SPR and the
concentration of the ligand present. Using this relationship it is possible to
calculate the concentration of CTA1 in cellular extracts from a translocation
assay. With this tool we determined the exact concentration of CTA1 that
reaches the cytosol and also how that amount was decreased by the inhibition of
Hsp90. The amount of CTA1 we found in the cytosol of untreated cells was
consistent with the inefficiency of the trafficking of cholera toxin from the cell
surface to the ER. The cells that were treated with NECA produced an SPR
signal similar to that observed in control cells. GA substantially reduced the
SPR signal from cells that were exposed to CT (Table 5-2).
To ensure that GA did not block the intracellular trafficking of CT, we
screened media samples from toxin-treated cells for the presence of free CTA1.
The reasoning for this experiment is that if we have secretion in one direction
then trafficking is working in both directions. In addition, a fraction of dissociated
CTA1 enters the secretory pathway and is released into the extracellular medium
(57, 60). Consistent with these observations, our SPR assay detected the
secretion of CTA1 from intoxicated HeLa cells (Fig. 5-5d). Nearly equivalent
amounts of CTA1 were secreted into the medium of untreated cells and cells

58

treated with GA. No signal was obtained from the medium of BfA-treated cells,
thus demonstrating that toxin trafficking to the ER was a prerequisite for CTA1
secretion into the medium. Secreted toxin was free CTA1 and not the CT
holotoxin because CT has a KDEL retention tag and once that is removed CTA1
can be secreted if stabilized. Since untreated and GA-treated cells released
equivalent amounts of free CTA1, GA did not appear to block holotoxin trafficking
to the ER, CTA1 dissociation from the rest of the toxin in the ER, or the secretion
of free CTA1.
The block of toxicity or the drop in cytosolic CTA1 could be a by product
of Hsp90 activity. To address these concerns we combined our dislocation
assay with a plasmid-based system to express CTA1 directly in the ER of
transfected CHO cells (65) in order to ensure that blocking Hsp 90 did not affect
any up stream trafficking step. CTA1 is co-translationally inserted into the ER
and then dislocated back to the cytosol. This strategy has been used by other
labs to monitor toxin progression to the cytosol (75-80). Control experiments
again demonstrated the fidelity of our fractionation protocol (Fig. 5-6a).
Consistent with the SPR-based dislocation assay, which used exogenously
applied toxin, this plasmid-based system detected a block of CTA1 dislocation to
the cytosol, in GA-treated cells (Fig. 5-6b). Little or no effect on CTA1 dislocation
was found for NECA-treated cells(Fig. 5-6).
It is common to have drug treatments to have unexpected effects either
up or downstream from your point of refrence. To address this we utilized RNAi.
We knocked down only Hsp 90 by RNAi and we repeated the toxicity assay to
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show that the results that we have demonstrated come from a loss of Hsp 90
activity alone (Fig. 5-7).
Toxin turnover could be responsible for this drop in toxicity for GA treated
cells. Very little toxin, that binds to the cell surface, actually progress to the ER
for translocation. If Hsp90 is affecting the turnover of cytosolic toxin, then the
loss of toxicity and observed translocation could be an artifact. To address this
issue we utilized our SPR translocation assay with the addition of proteasome
inhibitors (Fig. 5-8). Blocking the activity of Hsp90 with GA did not affect the
accumulation of CTA1 in the cytosol also demonstrating that the activity of Hsp90
is only at the site of translocation and not on any down stream effects (Fig. 5-8).
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Figure 5-5 Effect of the loss of Hsp 90 on CTA1 Translocation
GA but not NECA inhibits CTA1 dislocation to the cytosol. HeLa cells were
pulselabeled at 4°C for 30 min with 1 μg / ml of CT. The cells were then chased
for 2 hr at 37°C in toxin-free medium containing no additions, 0.1 μM GA, 0.1 μM
NECA, or 5 μg / ml of BfA. (A): Both fractions from untreated cells were probed
by Western blot to establish the distributions of cytosolic marker Hsp90 and ER
marker PDI. (B)The upper band represents the disulfide linked CTA1/CTA2
heterodimer; the middle band results from non-specific cross-reactivity; and the
lower band represents reduced CTA1. (C): An SPR sensor slide coated with an
anti-CTA antibody was used to detect the cytosolic pool of CTA1 from untreated
or drug-treated cells. (D): Media samples taken from cells at the end of the chase
were perfused over an SPR sensor slide coated with an anti-CTA antibody. For
both (C) and (D), CTA standards were perfused over the sensor slide as positive
controls. The cytosolic fraction and medium from unintoxicated cells were also
perfused over the sensor slides as negative controls for panels (C) and (D),
respectively. At the end of each experiment, bound sample was stripped from the
sensor slide. One of four representative experiments is show
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Figure 5-6 Effect of the loss of Hsp 90 on translocation of CTA1 into the
cytosol
GA inhibits dislocation of an ER-localized CTA1 construct. CHO cells were
transfected with a plasmid encoding a CTA1 subunit appended with an ERtargeting signal sequence. Permeabilization of the plasma membrane with
digitonin was used to partition cell extracts into separate organelle (pellet; P) and
cytosolic (supernatant; S) fractions. (A): Both fractions from transfected cells
were probed by Western blot to establish the distributions of Hsp90 and PDI. (B):
The distribution of CTA1 immunoprecipitated from transfected cells after a 1 hr
radiolabeling was visualized and quantified by SDS-PAGE with PhosphorImager
analysis. Experiments were performed with untreated control cells, cells exposed
to 0.1 μM NECA, or cells exposed to 0.1 μM GA. The upper band in the gel
represents the population of CTA1 with an intact, uncleaved signal sequence.
The means ± SEMs of three independent experiments is presented in the graph.
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Ligand Association rate
constant (1/Ms)

Calculated quantity

0.1 ng CTA standard

13,066

0.15 ng

1 ng CTA standard

24,753

0.45 ng

10 ng CTA standard

61,976

14 ng

100 ng CTA standard

83,668

104 ng

No treatment sample

17,064

0.22 ng

+ NECA sample

17,925

0.24 ng

+ GA sample

7,524

0.09 ng

Mock RNAi

15,373

0.19 ng

Control RNAi

14,890

0.18 ng

Hsp90 RNAi

3,489

0.06 ng

TABLE 5-2 Calculations of cytosolic CTA1
Association rate constants were calculated from the SPR data presented in
Figures 5-4C. The association rate constants for the CTA standards were plotted
as a function of protein quantity, and the slope of the resulting standard curve
was used to calculate the amount of CTA1 detected in the dislocation
experiments.
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Figure 5-7 Effect of the loss of Hsp 90 on CT toxicity
Transfected cells were exposed to varying concentrations of CT for 2 hr before
intracellular cAMP levels were determined. The means ± SEMs of 4 independent
experiments with triplicate samples are shown.
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Figure 5-8 Proteasome inhibition does not affect the accumulation of
cytosolic CTA1
HeLa cellswere pulse-labeled at 4C for 30 min with 1 g / ml of CT. The cells were
then chased for 2 hr at 37C in toxin-free medium that contained no additions, 100
M ALLN, 100 M MG132, 0.1 M GA, 0.1 M GA & 100 M ALLN, or 0.1 M GA & 100
M MG132. Selective permeabilization of the plasma membrane with digitonin
was used to partition cell extracts into separate organelle and cytosolic fractions.
An SPR sensor slide coated with an anti-CTA antibody was used to detect the
cytosolic pool of CTA1 from untreated (no treatment) or drug-treated cells. CTA
standards were perfused over the sensor slide as positive controls. In the time
frame of this 2 hr pulse-chase experiment, inhibition of the proteasome with
ALLN or MG132 did not alter the level of cytosolic CTA1 in either untreated or
GA treated cells. The disruption of proteasome function was confirmed with an
assay that detected an inhibition of bulk protein turnover in radiolabeled cells
exposed to ALLN or MG132.
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5.5 Discussion
Recently, Hsp90 was shown to be involved with the refolding of an
exogenously added protein that progressed from the cell surface to the ER and
from the ER to the cytosol (81). Hsp90 in that study assisted the refolding of the
unfolded, exogenously added protein. This activity may be linked to the
dislocation activity of Hsp 90. It is not a stretch to couple dislocation with
refolding. Hsp90 would extract CTA1 from the ER by refolding CTA1, thus
preventing CTA1 from returning into the translocation pore. This extraction
would thus provide the driving force for CTA1 dislocation. Although a previous
report suggested the ATP-dependent translocation of CTA1 does not require
cytosolic factors (76), we and others (75, 82) have detected a membraneassociated pool of Hsp90 which could easily been present in those previous
studies. Our work clearly shows that Hsp90 maintains a high affinity interaction
with CTA1, and that blocking of this interaction inhibits both CTA1 dislocation and
CT intoxication in vivo.
ERAD substrates are usually exported to the cytosol through the action of
p97 (70, 83). However, there is also a p97-independent dislocation route for
some ERAD substrates such as CTA1 (71, 72, 84, 85). This work demonstrates
that the p97-independent dislocation of CTA1 requires Hsp90 function. We have
thus established a new role for Hsp90 in the extraction of a soluble ERAD
substrate from the ER.
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CHAPTER 6 GENERAL DISCUSSION
Many AB protein toxins are category B agents on the CDC list of bioterrorism agents. Many AB toxins are also commonly associated with food- or
waterborne disease. While antibiotics are available to treat some of the
infections, prevention of toxin action is an ideal target for alternate therapeutic
approaches. AB toxins all face the same problem. They all bind to the cell
surface and must cross a membrane barrier to reach their cytosolic target. Some
of the AB toxins utilize ERAD to translocate into the cytosol. The use of one
pathway by so many toxins makes ERAD an ideal candidate for a therapeutic
target. Understanding the cell biology of intoxication will thus help to develop
novel, possibly broad spectrum, treatments for intoxication.
Our study began with the investigation of PDI and its role on cholera
intoxication. Within the ER, PDI serves to dislodge the A1 active subunit from the
rest of the holotoxin. Upon binding, PDI serves as nothing more than a wedge to
pry the active subunit of the toxin out of association with the rest of the holotoxin
where it is stably held. CTA1, without the stabilizing effect of the holotoxin,
spontaneously unfolds and becomes a normal candidate for ERAD-mediated
translocation out of the ER. Our results contradict one of the most cited and
entrenched ideas in toxin trafficking, that PDI is an unfoldase. The disruption of
PDI function results in decreased toxicity, confirming our initial hypothesis that
PDI is necessary for toxicity via holotoxin disassembly, but not for CTA1
unfolding. This insight gives a potential therapeutic target, as stabilization of
CTA1 disrupts CT intoxication.
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CT arrival in the ER triggers a series of events that results in CTA1 dissociation
from the rest of the holotoxin resulting in a shift in CTA1 structure to a partially
unfolded conformation. This partially unfolded conformation triggers export from
the ER to the cytosol, where CTA1 can act upon its cytosolic target. Here we
showed that stabilization of the CTA1 structure with PBA indeed prevented both
the translocation event and intoxication. PBA represented a prime candidate for
blocking CT toxicity by stabilizing CTA1 in the ER, thereby removing its ability to
gain entry into the cytosol. Unlike other chemical chaperones that have been
tested, PBA is commercially available, FDA approved, and generally well
tolerated. These PBA results confirms that stabilization of the A subunit of CT in
the ER will result in a loss of toxicity.
Toxicity not only requires that the A subunit of CT achieves a
translocation- competent conformation to gain entry into the cytosol, it also must
have an active translocate force to move out of the ER. For normal ERAD
substrates P97 is responsible for this active extraction, but studies have shown
that CTA1 is not acted on by p97. This extraction must therefore be carried out
by another protein or protein complex. Hsp 90 is a cytosolic chaperone that has
been linked to the extraction of AB toxins from the endosomes into the cytosol. It
has also has been located on the cytosolic face of the ER lumen. We
demonstrate that Hsp 90 is required for this extraction of CTA1 out of the ER into
the cytosol. Blocking the activity of Hsp90 results in a loss of toxicity for CT.
This loss of toxicity is due to its inability to translocate across the ER membrane.
Based on the collective results presented here, we have suggested an
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alternative to the current model of CTA1 translocation. It is currently believed
that CTA1 is a thermally stable protein that is actively unfolded in the ER by PDI.
We have shown that CTA1 attains an unfolded conformation at 37°C in the
absence of PDI. We have further shown that stabilization of CTA1 structure
disrupts the ERAD the translocation event and intoxication. We have also shown
that there is no toxicity without an active cytosolic partner to extract the
translocation competent CTA1.
This study demonstrates that CTA1 is stable only in association with the
holotoxin. When PDI removes this stabilization, CTA1 will unfold. Stabilization of
CTA1 by chemical chaperone PBA will keep CTA1 from achieving a
translocation-competent state. CTA1 will therefore be stuck in the ER until it is
degraded. Achieving a translocation-competent state is not enough for CTA1 to
gain exit from the ER; the cytosolic chaperone Hsp90 must also act to extract
CTA1 from the ER into the cytosol. These collective observations form the basis
for a new, substantially different model of CTA1 translocation.
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